Peter Salzmann . net worth and biography

Peter . Biography and Net Worth

of Immunovant

Peter Salzmann, M.D., M.B.A. is the Chief Executive Officer of Immunovant and a member of Immunovant’s board of directors. From November 2018 to June 2019, he served as a Global Development Leader in Immunology at Eli Lilly and Company, where he was responsible for the design of a comprehensive indication strategy and Phase 2 and 3 clinical trial execution. From May 2013 to October 2018, Dr. Salzmann was Head of U.S. Immunology at Eli Lilly, and he also served as Managing Director of Lilly Alps from January 2011 to April 2013. From January 2008 to December 2010, Dr. Salzmann was the Head of Marketing for Eli Lilly China.

Dr. Salzmann earned a B.A. in Chemistry from Northwestern University, an M.D. from University of Chicago’s Pritzker School of Medicine, and an M.B.A. from Stanford University’s Graduate School of Business.

How do I contact Peter Salzmann .?: The corporate mailing address for Dr. . and other Immunovant executives is 320 WEST 37TH STREET, NEW YORK NY, 10018. Immunovant can also be reached via phone at 917-580-3099 and via email at [email protected]. Learn More on Peter Salzmann .'s contact information.
Has Peter Salzmann . been buying or selling shares of Immunovant?: Peter Salzmann . has not been actively trading shares of Immunovant over the course of the past ninety days. Learn More on Peter Salzmann .'s trading history.
Who are Immunovant's active insiders?: Immunovant's insider roster includes Peter . (), Eva Barnett (CFO), Julia Butchko (Insider), Andrew Fromkin (Director), Michael Geffner (Chief Medical Officer), Tiago Girão (CFO), Melanie Gloria (COO), Douglas Hughes (Director), Mark Levine (Chief Legal Officer and Corporate Secretary), William Macias (Insider), George Migausky (Director), Atul Pande (Director), Peter Salzmann (CEO), Jay Stout (CTO), Frank Torti (Director), and Christopher Van Tuyl (Chief Legal Officer and Corporate Secretary). Learn More on Immunovant's active insiders.
Are insiders buying or selling shares of Immunovant?: During the last twelve months, Immunovant insiders bought shares 1 times. They purchased a total of 16,666,666 shares worth more than $349,999,986.00. During the last twelve months, insiders at the sold shares 22 times. They sold a total of 151,850 shares worth more than $3,746,475.49. The most recent insider tranaction occured on May, 1st when Director Robert Graham Susman sold 2,502 shares worth more than $67,979.34. Insiders at Immunovant own 1.8% of the company. Learn More about insider trades at Immunovant.
Information on this page was last updated on 5/1/2026.

Peter Salzmann . Insider Trading History at Immunovant

Peter Salzmann . Buying and Selling Activity at Immunovant

Immunovant Company Overview

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Today's Range

Now: $28.98

$28.64

$30.16

50 Day Range

MA: $26.14

$22.98

$29.49

2 Week Range

Now: $28.98

$13.52

$30.16

Volume

755,698 shs

Average Volume

1,437,975 shs

Market Capitalization

$5.90 billion

P/E Ratio

N/A

Dividend Yield